Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REVEAL-1 - A Phase 3, Randomized, Double-masked, Placebo-controlled, Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

NCT06625411 is registered in ClinicalTrials.gov with Viridian Therapeutics, Inc. as lead sponsor.

NCT NCT06625411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06625411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REVEAL-1 - A Phase 3, Randomized, Double-masked, Placebo-controlled, Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
Lead sponsor
Viridian Therapeutics, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 27, 2024
Completion date
November 15, 2026
Enrollment
132 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid eye disease